Patient characteristics at allogeneic HCT
| Patient characteristics . | All patients (N = 1082) . |
|---|---|
| Demographic characteristics | |
| Age, y, mean ± SD | 47.9 ± 14.4 |
| Age category, n (%) | |
| 12-17 | 55 (5.1) |
| 18-39 | 228 (21.1) |
| 40-64 | 799 (73.8) |
| Male, n (%) | 619 (57.2) |
| Region, n (%) | |
| South | 424 (39.2) |
| Northeast | 260 (24.0) |
| North Central | 236 (21.8) |
| West | 162 (15.0) |
| Insurance plan type, n (%) | |
| PPO | 537 (47.7) |
| HDHP | 244 (22.6) |
| POS | 151 (14.0) |
| HMO | 114 (10.5) |
| Comprehensive | 31 (2.9) |
| EPO | 15 (1.4) |
| Unknown | 11 (1.0) |
| Year of index date, n (%) | |
| 2016 | 147 (13.6) |
| 2017 | 294 (27.2) |
| 2018 | 297 (27.4) |
| 2019 | 263 (24.3) |
| 2020 | 81 (7.5) |
| Clinical characteristics | |
| Types of primary malignancy, n (%) | |
| Acute myeloid leukemia | 465 (43.0) |
| Myelodysplastic syndrome | 176 (16.3) |
| Acute lymphocytic leukemia | 159 (14.7) |
| Lymphoma | 132 (12.2) |
| Chronic myeloid leukemia | 34 (3.1) |
| Other | 116 (10.7) |
| NCICI, mean ± SD | 1.5 ± 1.6 |
| Prior chemotherapy treatment, n (%) | 847 (78.3) |
| Prior CAR-T infusion, n (%) | 2 (0.2) |
| Donor source, n (%) | |
| Peripheral blood | 851 (78.7) |
| Bone marrow | 117 (10.8) |
| Cord blood | 34 (3.1) |
| Unspecified | 80 (7.4) |
| Patient characteristics . | All patients (N = 1082) . |
|---|---|
| Demographic characteristics | |
| Age, y, mean ± SD | 47.9 ± 14.4 |
| Age category, n (%) | |
| 12-17 | 55 (5.1) |
| 18-39 | 228 (21.1) |
| 40-64 | 799 (73.8) |
| Male, n (%) | 619 (57.2) |
| Region, n (%) | |
| South | 424 (39.2) |
| Northeast | 260 (24.0) |
| North Central | 236 (21.8) |
| West | 162 (15.0) |
| Insurance plan type, n (%) | |
| PPO | 537 (47.7) |
| HDHP | 244 (22.6) |
| POS | 151 (14.0) |
| HMO | 114 (10.5) |
| Comprehensive | 31 (2.9) |
| EPO | 15 (1.4) |
| Unknown | 11 (1.0) |
| Year of index date, n (%) | |
| 2016 | 147 (13.6) |
| 2017 | 294 (27.2) |
| 2018 | 297 (27.4) |
| 2019 | 263 (24.3) |
| 2020 | 81 (7.5) |
| Clinical characteristics | |
| Types of primary malignancy, n (%) | |
| Acute myeloid leukemia | 465 (43.0) |
| Myelodysplastic syndrome | 176 (16.3) |
| Acute lymphocytic leukemia | 159 (14.7) |
| Lymphoma | 132 (12.2) |
| Chronic myeloid leukemia | 34 (3.1) |
| Other | 116 (10.7) |
| NCICI, mean ± SD | 1.5 ± 1.6 |
| Prior chemotherapy treatment, n (%) | 847 (78.3) |
| Prior CAR-T infusion, n (%) | 2 (0.2) |
| Donor source, n (%) | |
| Peripheral blood | 851 (78.7) |
| Bone marrow | 117 (10.8) |
| Cord blood | 34 (3.1) |
| Unspecified | 80 (7.4) |
Demographic and clinical characteristics of patients identified using the Merative MarketScan Commercial Claims and Encounters database between 1 January 2016 and 30 June 2020.
CAR-T, chimeric antigen receptor T cell; EPO, exclusive provider organization; HDHP, high-deductible health plan; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization.